GLP‑1 drugs for pets: Cornell trial
Cornell has started an 11‑week clinical trial testing AKS‑562c — a once‑weekly GLP‑1 Fc‑fusion candidate — in client‑owned cats to see if it safely reduces appetite and produces meaningful weight loss. (dvm360.com) This shows how GLP‑1‑style treatments have moved beyond human obesity care and into veterinary medicine, signaling the broad commercial and clinical reach of the class. (dvm360.com)
Glucagon-like peptide 1 is a gut hormone that rises after eating and tells the brain and pancreas that food has arrived. In people, drugs that copy that signal can slow stomach emptying, reduce appetite, and improve blood sugar control. (sciencedirect.com) Veterinary researchers have been eyeing the same pathway because too many pets carry too much weight. The Association for Pet Obesity Prevention’s 2024 survey says 61% of cats were overweight or obese, and 33% were clinically obese. (aaha.org) Cornell is now testing whether that human drug idea can work in house cats that live at home with owners, not in a lab colony. Its clinical trial is enrolling client-owned overweight or obese cats for an 11-week study of a drug candidate called AKS-562c. (cornell.edu) The setup is simple: ten weekly shots under the skin, with some cats getting the drug and others getting placebo saline. Cornell’s trial page says the goal is to see whether the treatment safely lowers appetite and produces meaningful weight loss. (cornell.edu) AKS-562c is not just a copy of a human injection with a cat label on it. Cornell and trade coverage describe it as a once-weekly glucagon-like peptide 1 fusion protein built by Akston so the drug stays in the body long enough for weekly dosing. (dvm360.com) That “fusion protein” part is the engineering trick. Drug designers attach the appetite-signal protein to a larger antibody-like fragment, which works like giving a small molecule a bigger backpack so the body clears it more slowly. (sciencedirect.com) Cornell is not starting from zero. Veterinary Practice News reported that preclinical work at Cornell found no observed adverse effects and drug levels consistent with weekly dosing before the team moved into client-owned cats. (veterinarypracticenews.com) The reason vets care is that feline weight loss is harder than “just feed less” makes it sound. Cornell’s trial page says up to 2 out of 3 cats weigh too much, and excess weight raises risks for diabetes, mobility problems, and shorter lives. (cornell.edu) Even if this drug works, it is being tested as an add-on, not a replacement, for food management. DVM360 says the study is evaluating AKS-562c as an adjunct to nutritional management of excess body condition, which means the drug is supposed to help a diet plan stick rather than erase the need for one. (dvm360.com) This is also a business signal as much as a medical one. Akston announced the study in November 2025, and Cornell’s live trial listing in April 2026 shows the pet version of the glucagon-like peptide 1 boom has moved from concept talk into real veterinary enrollment. (akstonbio.com) (cornell.edu) If the cats on AKS-562c lose weight without major side effects, the next question will not be whether people recognize the drug class. The next question will be whether owners and veterinarians treat pet obesity like chronic disease management, with weekly injections, follow-up visits, and long-term monitoring instead of a bag of “light” kibble and hope. (mdpi.com)
